Lv1
70 积分 2023-10-13 加入
The Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel–Trenaunay Syndrome to Guide Designing a Proof-of-Concept Clinical Trial for Novel Therapeutic Intervention
16天前
已完结
Rapamycin and treatment of venous malformations
28天前
已关闭
Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: Preliminary pharmacokinetics and pharmacodynamic data
28天前
已完结
Alpelisib in pediatric PIK3CA- and TIE-2–mutant vascular anomalies: a case series on safety, efficacy, and drug exposure
29天前
已完结
19F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers
1个月前
已完结
Who should be included in first-in-human trials? A systematic review of reasons
1个月前
已完结
Trilaciclib: First Approval
1个月前
已完结
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
1个月前
已完结
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis
1个月前
已完结
Navigating First‐in‐Human and Early‐Phase Patient Studies: Study Designs, Risk Mitigation, and Population Selection Challenges
1个月前
已完结
皖公网安备34019202002308
